Category: health

• July 15, 2025

  Exploring the Future of Oncolytic Immunotherapy

  Replimune is pioneering a novel class of cancer treatments based on oncolytic immunotherapies—herpes simplex viruses engineered to replicate within tumors, kill cancer cells directly, and spark systemic anti-tumor immunity ([Replimune][1]). The RPx Platform Replimune’s RPx platform uses modified HSV-1 backbones enhanced with immune‑stimulating transgenes: RP3: Adds co‑stimulatory ligands (CD40L and 4‑1BBL) to further stimulate immune…